This report analyzes the disruptive themes that have driven M&A activity in 2025 in the pharma Sector.
The global pharma sector in 2025 witnessed deals worth $232 billion, a growth of 40% compared to 2024. The Pharma sector recorded deal value worth $199 billion mega deals (defined as any deal valued at more than $1 billion) in 2025, an increase of 67% compared to 2024.
The global pharma sector in 2025 witnessed deals worth $232 billion, a growth of 40% compared to 2024. The Pharma sector recorded deal value worth $199 billion mega deals (defined as any deal valued at more than $1 billion) in 2025, an increase of 67% compared to 2024.
Report Scope
- This report provides an overview of merger and acquisition activity globally in 2025 in Pharma Sector
- It identifies the themes driving most notable to deals announced in 2025 in the Pharma Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
Table of Contents
- Executive Summary
- Review of the pharma M&A Market - 2025
- Pharma M&A Deals Analysis by Geography - 2025
- Further Reading
- Report Authors
- Appendix 1: Deal Selection Criteria
- Appendix 2: Thematic Research Methodology
- Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Abu Dhabi Investment Authority
- Blackstone Inc
- GIC Private Ltd
- TPG Capital LP
- Johnson & Johnson
- Novartis AG
- Merck & Co Inc
- Sanofi
- Thermo Fisher Scientific Inc
- Merck & Co Inc
- Genmab AS
- Pfizer Inc
- Exact Sciences Corp
- Hologic Inc
- Intra-Cellular Therapies Inc
- Avidity Biosciences Inc
- Verona Pharma Plc
- Blueprint Medicines Corp
- Clario
- Cidara Therapeutics Inc
- Merus NV
- Metsera Inc
